F
Fabrizio Pane
Researcher at University of Naples Federico II
Publications - 396
Citations - 18631
Fabrizio Pane is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Imatinib mesylate & Myeloid leukemia. The author has an hindex of 57, co-authored 362 publications receiving 16240 citations. Previous affiliations of Fabrizio Pane include University of Bari.
Papers
More filters
Journal ArticleDOI
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Journal ArticleDOI
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
Jean Gabert,Emmanuel Beillard,V H J van der Velden,Wanli Bi,David Grimwade,Niels Pallisgaard,Gisela Barbany,Giovanni Cazzaniga,Jean Michel Cayuela,Hélène Cavé,Fabrizio Pane,J. L. E. Aerts,D De Micheli,X Thirion,V Pradel,Marcos González,Susanne Viehmann,Maria Malec,Giuseppe Saglio,J. J. M. Van Dongen +19 more
TL;DR: The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels and is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials.
Journal ArticleDOI
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani,Jorge E. Cortes,Fabrizio Pane,Dietger Niederwieser,Giuseppe Saglio,Jane F. Apperley,Francisco Cervantes,Michael W. Deininger,Alois Gratwohl,François Guilhot,Andreas Hochhaus,Mary M. Horowitz,Timothy P. Hughes,Hagop M. Kantarjian,Richard A. Larson,Jerald P. Radich,Bengt Simonsson,Richard T. Silver,John M. Goldman,Rüdiger Hehlmann +19 more
TL;DR: Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.
Journal ArticleDOI
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus,Michele Baccarani,Richard T. Silver,Charles A. Schiffer,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,Michael W. Deininger,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Jeroen Janssen,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,Francois-Xavier Mahon,Jiří Mayer,Franck E. Nicolini,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Delphine Rea,Johan Richter,Gianantonio Rosti,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Simona Soverini,Juan Luis Steegmann,Anna G. Turkina,Andrey Zaritskey,Ruediger Hehlmann +33 more
TL;DR: An expert panel to critically evaluate and update the evidence to achieve goals to achieve a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR) in chronic myeloid leukemia.
Journal ArticleDOI
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Martin Griesshammer,Tamás Masszi,Simon Durrant,Francesco Passamonti,Claire N. Harrison,Fabrizio Pane,Pierre Zachee,Ruben A. Mesa,Shui He,Mark M. Jones,William M. Garrett,Jingjin Li,Ulrich Pirron,Dany Habr,Srdan Verstovsek +16 more
TL;DR: In patients who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib was superior to standard therapy in controlling the hematocrit, reducing the spleen volume, and improving symptoms associated with polycythemia vera.